Medpace (NASDAQ:MEDP) Director Robert Kraft Sells 3,858 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) Director Robert Kraft sold 3,858 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $617.81, for a total value of $2,383,510.98. Following the completion of the sale, the director owned 955 shares in the company, valued at approximately $590,008.55. The trade was a 80.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Medpace Price Performance

Shares of MEDP opened at $600.65 on Friday. The company has a 50-day moving average of $565.33 and a 200 day moving average of $494.55. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The firm has a market capitalization of $16.76 billion, a price-to-earnings ratio of 35.21, a PEG ratio of 2.73 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on MEDP. Mizuho lifted their target price on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. TD Cowen upped their target price on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Robert W. Baird increased their price target on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. Truist Financial lifted their price objective on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Finally, Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and increased their price target for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Three research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, Medpace presently has a consensus rating of “Hold” and a consensus price target of $584.18.

Institutional Trading of Medpace

Several large investors have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC raised its holdings in shares of Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after acquiring an additional 190 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Medpace by 3.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after purchasing an additional 3,010 shares during the period. Geneos Wealth Management Inc. increased its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Sivia Capital Partners LLC purchased a new position in Medpace during the second quarter worth about $296,000. Finally, M&T Bank Corp raised its stake in Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after purchasing an additional 31 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.